SGLT2 Is Tied to Fewer Post-MI Deaths in T2D SGLT2 Is Tied to Fewer Post-MI Deaths in T2D
Observational registry data from Sweden showed a significant link between SGLT2 inhibitor use at the time of an MI in people with type 2 diabetes and fewer all-cause deaths in 1-year follow-up.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news
More News: Cardiology | Diabetes | Diabetes Type 2 | Endocrinology | Heart | SGLT2 Inhibitors | Sweden Health